492. An Enhanced DC-Targeting Lentivector Vaccine to HIV-1 Gag by PD-1 Blockade

Molecular Therapy - United States
doi 10.1016/s1525-0016(16)37065-4
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Elsevier BV

Related search

P17-14. Fitness-Informed HIV-1 Gag-P24 Vaccine Design

Retrovirology
VirologyInfectious Diseases
2009English

Phase I Safety and Immunogenicity Evaluations of an Alphavirus Replicon HIV-1 Subtype C Gag Vaccine in Healthy HIV-1-Uninfected Adults

Clinical and Vaccine Immunology
MedicineImmunologyAllergyClinical BiochemistryMicrobiology
2012English

PD-1 Expression and Clinical PD-1 Blockade in B-Cell Lymphomas

Blood
BiochemistryImmunologyCell BiologyHematology
2018English

Regulation of HIV-1 Gag-Pol Expression by Shiftless, an Inhibitor of Programmed -1 Ribosomal Frameshifting

Cell
BiochemistryGeneticsMolecular Biology
2019English

Safety and Immunogenicity of a Gag-Pol Candidate HIV-1 DNA Vaccine Administered by a Needle-Free Device in HIV-1-Seronegative Subjects

Journal of Acquired Immune Deficiency Syndromes
Infectious DiseasesPharmacology
2007English

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Breast Care
SurgeryOncology
2016English

PD-1 Checkpoint Blockade in Combination With an mTOR Inhibitor Restrains Hepatocellular Carcinoma Growth Induced by Hepatoma Cell-Intrinsic PD-1

Hepatology
MedicineHepatology
2017English

PAK4 Inhibition Improves PD-1 Blockade Immunotherapy

Nature Cancer
2019English

Oncolytic Virus and PD-1/PD-L1 Blockade Combination Therapy

Oncolytic Virotherapy
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy